SB 983, the Hearing Device Coverage Clarification Act, would require the Administrator of the Centers for Medicare & Medicaid Services to clarify within 60 days of enactment that implanted active middle ear hearing devices are treated as prosthetics under Medicare. The bill specifically states that these devices would not be subject to Medicare’s hearing aid coverage exclusion in section 1862(a)(7) of the Social Security Act.
In practical terms, the measure is aimed at ensuring Medicare coverage for a category of implanted hearing technology by placing it within the prosthetic-device framework rather than the hearing-aid exclusion. The bill also defines “prosthetic” by reference to existing federal regulations, tying the clarification to current CMS regulatory language rather than creating a new standalone definition.
Impact
If enacted, the bill would direct CMS to issue a coverage clarification that could expand Medicare reimbursement eligibility for implanted active middle ear hearing devices. It would affect the administration of Medicare benefits and the interpretation of the hearing aid exclusion in the Social Security Act, potentially benefiting Medicare beneficiaries who need these implanted devices and providers who furnish them. The bill does not itself amend the statutory exclusion text, but it would require CMS to interpret and apply existing law in a way that treats these devices as prosthetics.
Sentiment
The available context suggests generally supportive sentiment. The bill was introduced by Senators Klobuchar and Lankford, indicating bipartisan sponsorship, and there is no recorded committee debate or vote history in the provided materials showing opposition or controversy. Its referral to the Senate Finance Committee suggests it is being handled as a Medicare coverage issue rather than a broader policy dispute.
Contention
The main substantive issue is whether implanted active middle ear hearing devices should be classified as prosthetics eligible for Medicare coverage or as hearing aids excluded from coverage. Any contention would likely center on the scope of Medicare coverage, CMS’s authority to interpret the exclusion, and the potential cost implications for the program. No specific objections, amendments, or opposing arguments are included in the provided record.